Protozoa as Synthetic Biology Chassis

Protozoan chassis like Leishmania tarentolae combine the best of both worlds: eukaryotic protein folding and modification machinery with bacterial-like growth simplicity. They offer mammalian-type glycosylation, proper disulfide bond formation, and rapid growth rates (6-8 hour doubling time) at 26°C without requiring expensive cell culture equipment. This results in high yields (up to 500 mg/L) with authentic post-translational modifications.

Constitutive expression systems continuously produce your target protein using strong RNA polymerase I promoters. They are ideal for non-toxic proteins and allow co-expression of up to four different proteins simultaneously. Inducible systems (using tetracycline control) allow temporal regulation and can achieve 10-100x higher yields for potentially toxic proteins since expression can be triggered after cells reach optimal density. We recommend inducible systems for proteases, nucleases, and membrane proteins.

LEXSY performs mammalian-type N-glycosylation with biantennary, core-α-1,6-fucosylated structures similar to CHO cells. Unlike yeast (high-mannose) or insect cells (paucimannosidic), LEXSY-produced proteins show homogeneous glycosylation profiles without the heterogeneity common in mammalian systems. This makes LEXSY particularly valuable for structural biology where consistent glycosylation is critical for crystallization.

Our platforms excel with challenging proteins that fail in bacterial systems: multi-pass membrane proteins, proteins requiring complex glycosylation, large protein complexes, disulfide-bond-rich proteins, and proteins where authentic folding is essential. We have successfully expressed kinases, antibodies, viral antigens, growth factors, receptors, and enzymes. For standard simple proteins, bacterial or yeast systems may be more cost-effective.

Leishmania tarentolae is classified as Biosafety Level 1 (BSL-1), making it one of the safest eukaryotic expression systems available. It cannot infect mammals and requires no special containment equipment. Trypanosoma brucei brucei strain 427 is BSL-2 due to its potential mammalian infectivity, but standard molecular biology laboratories can work with it following established protocols.

Standard projects from gene synthesis to purified protein typically take 6-12 weeks. Vector construction requires 2-3 weeks, expression screening 2-3 weeks, and scale-up with purification 2-4 weeks depending on yield and purity requirements. Rush services are available for time-sensitive projects. Initial consultation and project assessment are provided within 1-2 business days.

Yes, we offer comprehensive CRISPR-Cas9 services for Trypanosoma and Leishmania species. Our capabilities include gene knockout, knock-in, point mutation introduction, epitope tagging, and conditional expression system development. We handle everything from sgRNA design and vector construction to clone validation and phenotype characterization. RNA interference (RNAi) services are also available for T. brucei.

We offer scalable production from milligram to multi-gram quantities. Standard service includes small-scale screening (1-10 mL), with options for mid-scale (100 mL-1 L) and large-scale production (10-100 L). Our high-density fermentation protocols achieve cell densities up to 10^9 cells/mL, enabling efficient production of even low-expression proteins. Purification can be customized from crude lysate to 95%+ purity.